Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 10/20 | 0.36 |
| ▸ | PPARG | P37231 | 10/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22805329 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2PTGDR2PPARAPPARGPPARD | |
| SCHEMBL28694757 | 0.91 | PPARG (0.34) | PTGDR2PPARAPPARGPPARDAAK1 | |
| SCHEMBL22823742 | 0.91 | PPARG (0.34) | PTGDR2PPARAPPARGPPARDAAK1 | |
| SCHEMBL29368185 | 0.91 | PPARG (0.34) | PTGDR2PPARAPPARGPPARDAAK1 | |
| SCHEMBL22823750 | 0.88 | AAK1 (0.34) | MAPTAAK1 | |
| SCHEMBL29602077 | 0.88 | AAK1 (0.34) | MAPTAAK1 | |
| SCHEMBL28676309 | 0.87 | PPARG (0.32) | PPARAPPARGAAK1 | |
| SCHEMBL22823914 | 0.86 | AAK1 (0.36) | SMN1; SMN2PTGDR2PPARAPPARGPPARD | |
| SCHEMBL22820787 | 0.86 | AAK1 (0.36) | SMN1; SMN2PTGDR2PPARAPPARGPPARD | |
| SCHEMBL29365429 | 0.86 | AAK1 (0.36) | SMN1; SMN2PTGDR2PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| EP-3986852-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-10-16 | — | — | EP | disclosed |
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-12-08 | — | — | US | disclosed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020254559-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CACNB1, SMN1; SMN2 | SMN1; SMN2 3/4885PTGDR2 2994/4885PPARA 3710/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | SMN1; SMN2 3/4885PTGDR2 2994/4885PPARA 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.